Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.00
+2.1%
$0.98
$0.61
$7.45
$15.08M-0.151.14 million shs294,547 shs
Aptorum Group Limited stock logo
APM
Aptorum Group
$0.97
-1.9%
$0.98
$0.46
$7.49
$5.19M-0.14622,116 shs25,794 shs
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$1.17
-2.0%
$1.28
$0.87
$2.55
$22.06M0.47219,735 shs69,875 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.22
-6.9%
$3.23
$2.57
$6.88
$19.90M0.639,134 shs25,168 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00%+7.52%+12.15%-3.86%-83.42%
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00%-1.87%+5.60%+9.77%-79.63%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
0.00%-2.50%-14.13%+3.54%+17.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.72%-4.17%-8.00%-49.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.7852 of 5 stars
0.04.00.00.01.40.01.3
Aptorum Group Limited stock logo
APM
Aptorum Group
1.169 of 5 stars
0.03.00.00.03.31.70.6
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2.7883 of 5 stars
3.53.00.00.02.71.70.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.8426 of 5 stars
0.03.00.00.02.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00
N/AN/AN/A
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00
N/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50626.50% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest APM, ALLR, NAII, and CMMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
Aptorum Group Limited stock logo
APM
Aptorum Group
$430K12.09N/AN/A$2.20 per share0.44
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.17N/AN/A$13.32 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)
Aptorum Group Limited stock logo
APM
Aptorum Group
-$4.27MN/A0.00N/AN/AN/AN/A7/30/2025 (Estimated)
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A

Latest APM, ALLR, NAII, and CMMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$8.10-$0.25+$7.85-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.66
2.66
Aptorum Group Limited stock logo
APM
Aptorum Group
N/A
0.22
0.22
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
5.33
5.33
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
Aptorum Group Limited stock logo
APM
Aptorum Group
3.80%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
46.05%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1015.08 million15.07 millionNot Optionable
Aptorum Group Limited stock logo
APM
Aptorum Group
305.35 million1.93 millionNot Optionable
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2018.86 million16.61 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
CarnoSyn Brands announces new U.S. distribution pact with B&D Nutritional
(NAII) Trading Advice
In Asia, alternative proteins are the new clean energy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$1.00 +0.02 (+2.12%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.00 +0.01 (+0.51%)
As of 06/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Aptorum Group stock logo

Aptorum Group NASDAQ:APM

$0.97 -0.02 (-1.87%)
Closing price 06/27/2025 03:52 PM Eastern
Extended Trading
$0.97 +0.00 (+0.26%)
As of 06/27/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.17 -0.02 (-1.98%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$1.17 0.00 (0.00%)
As of 06/27/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.25 -0.21 (-6.07%)
As of 06/27/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.